JPM
JPMorgan Chase & Co.
stock NYSE

UFOs are real! But I'm not going to prove it....trust me bro.  Do you realize how crazy that sounds.
Prove JPM owns 100% of that unallocated silver.  See, you can't! 

Come on you gotta try a little harder with troll like this.
SoFi is one crisis away from bankruptcy while fortresses like JPM are going to get their pick of whatever is left of them.

Then why is placing tariffs additional tariffs on Europe and taking JPM to court?

We all have lives. We can enjoy our lives the way that we want. If buy and hold makes sense then go ahead. I’ve held AAPL, AMZN, MSFT for 20 years ? But what companies can one look at now and possibly hold so faithfully. NVDA, AVGO, JPM, AMD, INTC, MU, gold ? Thems slim pickings.
Markets trending for long periods favor holding. But crashes and drawdowns can forces selling at the worse times and having income by selling shares takes away the assets being held. After a crash one is required to sell off more and more percentage of assets for income. Trading allows one to hold the devalued assets while still creating income. There are advantages to doing both. So buy and hold and trading go hand in hand for success. As someone who trades thousands of times yearly I can say “traders” mostly do both.

>All three companies dominate spatial genomics, proteomics, and transcriptomics. I won’t go into too kuhh ch detail but every information is public. I’ll tell you this much, there’s 10x genomics, illumina is fillings it’s toe, PAC Bio, Akoya and probably a couple more, I would say Bruker dominates all of them. That’s not my opinion but just a fact. Look at their conference presentations (AGBT etc) and their JPM presentations.
When you say "dominates all of them", in what sense are you referring to? Because I also "work in the domain" (as a customer) and I've never even heard of Bruker. I just checked out equipment for a few top R1 university sequencing cores and of course, none of them have any Bruker. Cool - they bought NanoString, but NanoString is super unpopular compared to Visium because it's not true spatial, it just gets you high confidence cell phenotype calls and you lose the spatial context because you have to disassociate prior to sequencing.
>Now the question is how viable is spatial genomics? Current state of the art is sequencing techniques that illuminate and Oxford nanopore offer. These seducing techniques along with Chip Seq methods don’t visualize the genome and don’t tell the whole story (because proteins have characteristics that genes can’t fully explain). All this to say that spatial biology is not going anywhere.
I think this says it all: you clearly have no understanding of molecular biology and are just mashing words together hoping something sticks
I don't get this post at all. Not even saying Bruker won't do well, maybe they will do great, but you claim to understand the domain in depth, and readers should understand that it's pretty clear that you don't

If you’re not a major and unless you are a boutique firm with some serious expertise in an area, You’re basically WSB with some guys that hit Their ceiling at GS/JPM/etc
You’re giving us a PR line, zero data where are the in trials, efficacy rates, etc, but on the plus side they have a “strategy”
Turning literal shit into gold is so hard. A company that will succeed with this, will be very successful.
Good luck, paperhands

ETA - No positions and your DD is some Shitco initiating coverage

Good information, thank you. JPM switching net long is interesting.
https://preview.redd.it/nmf1xdhq43eg1.png?width=1212&format=png&auto=webp&s=8f6f7365c07050802f53d5533dc9c9c612113856

Yea the JPM owns and holds 750 narrative is fake news.  Anyone that thinks otherwise needs to back up the claim which can't be done

Ok so a few disclaimers:
1. I am invested in Bruker
2. I am very familiar with Bruker and it’s products. I work in that domain and know about their competitors
With the risk of doxing myself and potential conflict of interest that might arise, I’ll be keeping things vague.
Before 2020, Bruker was trading at 53ish dollars. The came COVID and it crashed. From there it’s peaked a couple of times and but it’s 4 year moving average (from 2020 to end of 2024) was \~ 60. It was organically going to move only up. Then came 2025 and with it Trumps presidency.
Now I won’t get political but one very direct effect of trumps policies was the extreme reduction of NIH and in general science funding. Mix with DOGE and US science market and general R and D in non profits took a big hit. That’s a big market for Bruker.
You have to understand what Bruker does. They do deep tech. They build tools that enable other people to either build better tools or perform research. From their MALDI system (for mass spec) to their ability to build MRI tech, their dominance in NMR, their optical systems, metrology systems, and plethora of other tech. Now they have a division called Bruker Nano. Las few years Bruker stretched itself and bought a ton of small companies. Some are going while other failed. Bruker invested heavily in a ton of new tech from instrumentation to genomics/proteomics to even CRISPR. Spatial biology ended up sticking very well. So well that Bruker acquired nano string. Bruker already owned canopy and had a new company spin out called Bruker spatial genomics. All three companies dominate spatial genomics, proteomics, and transcriptomics. I won’t go into too kuhh ch detail but every information is public. I’ll tell you this much, there’s 10x genomics, illumina is fillings it’s toe, PAC Bio, Akoya and probably a couple more, I would say Bruker dominates all of them. That’s not my opinion but just a fact. Look at their conference presentations (AGBT etc) and their JPM presentations. Now the question is how viable is spatial genomics? Current state of the art is sequencing techniques that illuminate and Oxford nanopore offer. These seducing techniques along with Chip Seq methods don’t visualize the genome and don’t tell the whole story (because proteins have characteristics that genes can’t fully explain). All this to say that spatial biology is not going anywhere.
Now back to Bruker. Bruker is one of those companies that for some reason is not favored by investors. But if you look at its fundamentals they are very strong. Mass spec, NMR, spatial biology (just to name a few) are going no where. For example, Biohub (formerly known as CZI) is an institution created by Priscilla Chan and Mark Zuckerberg. Majority of their work is going to be imaging and omics based. They’ll be doing what’s called multimodal analysis. Lots of other people are going to be doing the same. All this to then further push the idea that Bruker is not going anywhere. No way is it simply a 7.35 Billion USD market cap.
Now onto investors. Blackrock, Vanguard, T rowe Price and others have dedicated index funds holding this stock. Which also baffles me because why would people underestimate this stock when bug investors know what we don’t.
Now why is the stock dropping- volatility. This stock goes up and then down and variance is very high. Last year it’s low was 38 and high was 64. This year it went back up to 54and now it’s dropped back to 48. Lots of negative news around it but nothing about their products or the management. Everything about lack of funding. That’s no reason you devalue Bruker. Also brokers Q2 2025 was weak but Q3 beat earnings and Q4 will have a higher EPS. Now yes Bruker will lose revenue in general but their profits won’t be affected because they’re cutting down. Once again, all this means that this company is financially strong and builds cutting edge tech. Why on earth are investors still pulling back is bizarre to me.
I will hold this stock. I guess one reason I wrote this post is because the stock has been tanking and now EU might suspend trade with US further affecting stock (maybe?). But I still believe this company is cooking some cool shit. My price target for this stock is at least 90. That’s what the company is worth (approx 15 billion).
I welcome any perspective folks have.
Thanks!

JPM got wind that Chinese buyers were going to purchase a gorillion ozs somewhere. At that time They had already passed along the majority of their shorts. The final nail was the inside scoop that silver was likely to bone.
I informed the reddit masses that we would eventually have some strange bedfellows
We win

What’s left in the US is that US companies will be getting that oil in Venezuela and buying up land in Africa for giant solar powered data centers all with capital raised by JPM, Goldman Sachs and black stone

I think trump has a point here: the power of organisations like JPM needs to be regulated on such topics

JPM can debank anyone they want.
Trump is mad because:
1) Jamie Dimon wouldn't let JPM "donate" to the Trump ballroom because as Dimon said it, the bank is concerned with the long term and has to consider future justice department inquiries into bribery during the Trump administration.
2) Dimon openly supports independent FOMC.
3) Dimon understands that if you cap credit card interest rates banks just won't issue credit cards to poor people at all.

JPM calls if it dips.

JPM shares Monday 🚀

The majority our this sub believes silver is/was a distraction and nothing more.
I assure you, as a 15 yr student of commodities/ metals trading & markets it is not.   
Gold and silver have been shorted since '73 when we officially abandoned the gold standard.  The COMEX was established specifically to manage the values of gold and silver.   Over the decades, the major players accumulated 'legacy shorts' , an ever growing mountain of naked shorts on metals to suppress the price .  For the past 15 years JPMorgan has led the way as custodian of the ETF, SLV.   They, and they alone have switched net long, amassing a 725M oz physical stockpile.  JPM pied piper-ed the other bullion banks, leading them to their doom.   UBS, CITIBANK, DEUTSCHE, HSBC & a few other have astounding short positions with dollar cost averages all under $30.  The East, spearheaded by the Shanghai gold exchange, is driving physical demand and canceled nearly all outflows from their refineries, which process 75% of global silver mining.   The current price doesn't yet reflect a squeeze, as open interest on the comex hasn't dramatically dropped.   They are str8 fuct and , unlike GME, they can't simply print synthetic ounces of silver.  They are all stuck and will suffer margin calls and probable liquidations in the next 6-12 months.    Should this happen, they will be obligated to close all short positions before selling assets to raise cash to close the silver shorts
As a heavy investor in both silver and GME, representing 100% of my liquid assets,, ll this time I expected GME to eventually squeeze &cause a subsequent squeeze in metals.   Looks like I had it backwards
Tl;dr:  the banks are truly short on metals.  The more they rise, the greater pressure the SHF's feel.   Cheer on the shiny shit, it may very well be our catalyst
Smooth 🧠 💎 👊-ed 🦧 to the 🌙 

He’s a narcissist who can do no wrong. So since JPM acted against him, they must be wrong and punished so everyone knows Trump was right

Buy the dip immediately. I just bought JPM on Friday.

The response of other nations might affect it, but I have no clue. Also there's the JPM Chase thing

What is going on with JPM or is this just a visual bug?